KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Cash from Operations (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Cash from Operations for 16 consecutive years, with 124200000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Cash from Operations rose 53.33% to 124200000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was 455200000.0, a 21.42% increase, with the full-year FY2024 number at 455200000.0, up 21.42% from a year prior.
  • Cash from Operations was 124200000.0 for Q4 2024 at Bio-Rad Laboratories, down from 163600000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 284728000.0 in Q4 2020 to a low of 50500000.0 in Q1 2022.
  • A 5-year average of 122069142.86 and a median of 97888500.0 in 2023 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: plummeted 53.41% in 2022, then surged 94.3% in 2023.
  • Bio-Rad Laboratories' Cash from Operations stood at 284728000.0 in 2020, then plummeted by 39.99% to 170864000.0 in 2021, then tumbled by 53.41% to 79610000.0 in 2022, then grew by 1.75% to 81004000.0 in 2023, then surged by 53.33% to 124200000.0 in 2024.
  • Per Business Quant, the three most recent readings for BIO's Cash from Operations are 124200000.0 (Q4 2024), 163600000.0 (Q3 2024), and 97600000.0 (Q2 2024).